Senolytics Improve Recovery Following a Heart Attack


In a new study, researchers show that the presence of senescent cells is an important contributor to aging of the cardiovascular system, particularly the heart [1].

To do this, we need your support. Your charitable contribution tranforms into rejuvenation research, news, shows, and more. Will you help?

Senescent cells and senolytics

As your body ages, increasing amounts of your cells enter into a state of senescence. Senescent cells do not divide or support the tissues of which they are part; instead, they emit a range of potentially harmful inflammatory chemical signals, which are known as the senescence associated secretory phenotype (SASP). The SASP can also encourage other nearby healthy cells to also enter the same senescent state.

Their presence causes many problems: they degrade tissue function, increase chronic inflammation, and can even eventually raise the risk of cancer. Senescent cells normally destroy themselves via a programmed process called apoptosis, and they are also removed by the immune system; however, the immune system weakens with age, and increasing numbers of these senescent cells escape this process and accumulate.

One possible solution to this problem is to remove senescent cells in order to improve tissue regeneration and health. A class of drugs called senolytics focuses on the destruction of these stubborn, “death-resistant” cells, thus reducing inflammation and improving tissue function.

Aiding recovery from heart attacks

Senescent cells are known to contribute to hypertrophy, in which the heart becomes enlarged and less able to pump blood. The presence of senescent cells is also linked to fibrosis in the heart tissue, which causes structural and functional failure.

The SASP increases systemic inflammation and creates a background of inflammaging, the chronic inflammation that is typically seen in older people. This chronic inflammation is harmful to all cells and tissues, and it impairs regeneration while contributing to vascular aging. Arterial stiffening via dysfunction of the smooth muscle cells and the development of atherosclerosis via macrophage dysfunction are two ways in which senescent cells promote vascular aging.

These researchers investigated if the senolytic clearance of senescent cells following a heart attack would improve survival odds in mice. They used the repurposed cancer drug navitoclax, a drug that targets the Bcl-2 family of proteins, a pro-survival pathway that has consistently turned up in the literature as one that many senescent cells use to avoid destruction. Various studies have shown that targeting this particular family of proteins allows the selective destruction of senescent cells.

This study showed that removal of senescent heart cells from mice reduced the development of fibrotic tissue and myocardial remodeling, improved diastolic function, and increased survival odds following a heart attack.


Cardiovascular disease is the leading cause of death in individuals over 60 years old. Aging is associated with an increased prevalence of coronary artery disease and a poorer prognosis following acute myocardial infarction (MI). With age, senescent cells accumulate in tissues, including the heart, and contribute to age‐related pathologies. However, the role of senescence in recovery following MI has not been investigated. In this study, we demonstrate that treatment of aged mice with the senolytic drug, navitoclax, eliminates senescent cardiomyocytes and attenuates profibrotic protein expression in aged mice. Importantly, clearance of senescent cells improved myocardial remodelling and diastolic function as well as overall survival following MI. These data provide proof‐of‐concept evidence that senescent cells are major contributors to impaired function and increased mortality following MI and that senolytics are a potential new therapeutic avenue for MI.


Once again, the role of senescent cells in aging has been confirmed, as has the plausibility of clearing these problem cells from the body to improve tissue health and regeneration and to prevent disease progression. Senolytics are currently in human trials, and studies like this only serve to add to the ever-growing pool of data in support of senescent cell removal as a way to combat age-related diseases by targeting this underlying aging process itself.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. We are committed to responsible journalism, free from commercial or political influence, that allows you to make informed decisions about your future health.

All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent journalism and sustains our future. You can support us by making a donation or in other ways at no cost to you.

Study: Waist-to-Hip Ratio Predicts Mortality Better Than BMI

A new study suggests that waist-to-hip ratio (WHR) has a more linear correlation with all-cause mortality than either body mass...

Restoring Heart Regeneration With a Metabolic Switch

In a recent article in Nature, researchers have restored cardiac regeneration to adult mice by disabling fatty acid oxidation, discovering...

Human Clinical Trials of NMN for Safety and Effectiveness

In a recent paper, researchers reviewed the literature for human clinical trials that address NMN's safety and anti-aging effects [1]....

Lifespan News – Elon Musk and the Living Forever Curse

On this episode of Lifespan News, Ryan O'Shea ruminates on Elon Musk's statement on living forever being a curse rather...


[1] Walaszczyk, A., Dookun, E., Redgrave, R., Tual‐Chalot, S., Victorelli, S., Spyridopoulos, I., … & Richardson, G. D. (2019). Pharmacological clearance of senescent cells improves survival and recovery in aged mice following acute myocardial infarction. Aging cell, e12945.

About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 600 articles on the topic, interviewed over 100 of the leading researchers in the field, hosted livestream events focused on aging, as well as attending various medical industry conferences. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, Swiss Monthly, Keep me Prime, and New Economy Magazine. Steve is one of three recipients of the 2020 H+ Innovator Award and shares this honour with Mirko Ranieri – Google AR and Dinorah Delfin – Immortalists Magazine. The H+ Innovator Award looks into our community and acknowledges ideas and projects that encourage social change, achieve scientific accomplishments, technological advances, philosophical and intellectual visions, author unique narratives, build fascinating artistic ventures, and develop products that bridge gaps and help us to achieve transhumanist goals. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project.
No Comments
Write a comment:


Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.